+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immunotherapy Drugs Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805791
The global immunotherapy drugs market value was USD 199.7 billion in 2022, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 11.2% during the forecast period of 2023-2031 to achieve a value of USD 519.2 billion by 2031.

Introduction

Immunotherapy drugs, also known as immune checkpoint inhibitors, are a revolutionary class of medications designed to harness the power of the immune system to fight cancer. Unlike traditional cancer treatments such as chemotherapy and radiation, which directly target cancer cells, immunotherapy works by stimulating the body's own immune system to recognize and destroy cancer cells.

The immune system has the remarkable ability to detect and eliminate abnormal cells, including cancer cells. However, cancer cells often develop mechanisms to evade the immune system's detection and attack. Immunotherapy drugs work by blocking these mechanisms, allowing the immune system to recognize and target cancer cells effectively.

One of the most significant advancements in immunotherapy is the development of immune checkpoint inhibitors, which target proteins on immune cells or cancer cells that regulate immune response. By blocking these proteins, immune checkpoint inhibitors can unleash the immune system's full potential to attack cancer cells.

Key Trends in the Immunotherapy Drugs Market

Some key trends involved in the immunotherapy drugs market are as follows:
  • Advancements in Precision Medicine: The field of immunotherapy is witnessing a shift towards precision medicine approaches. Researchers are focusing on identifying specific biomarkers and genetic profiles that can help predict patient response to immunotherapy drugs. This enables healthcare professionals to tailor treatment plans based on individual patient characteristics, improving treatment outcomes and reducing potential side effects
  • Combination Therapies: Combination therapies involving immunotherapy drugs and other treatment modalities are becoming increasingly common. By combining immunotherapy with chemotherapy, targeted therapy, or radiation therapy, healthcare providers aim to enhance treatment effectiveness and overcome resistance. These combination approaches have shown promising results in clinical trials and are expected to become more prevalent in the treatment of various cancers
  • Expansion of Indications: Initially, immunotherapy drugs were primarily used for the treatment of advanced-stage cancers. However, ongoing research and clinical trials have led to the expansion of indications for immunotherapy. These drugs are now being tested in earlier stages of cancer, as adjuvant or neoadjuvant therapy, and in combination with other standard treatments. This trend opens up new possibilities for the use of immunotherapy in a wider range of cancer types and disease stages

Immunotherapy Drugs Market Segmentations

Market Breakup by Drug Class

  • Monoclonal Antibodies
  • Adult Vaccines
  • Checkpoint Inhibitors
  • Interferons Alpha and Beta
  • Interleukins
  • Other Drugs

Market Breakup by Applications

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by End User

  • Hospitals
  • Specialty Centres
  • Clinics
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Immunotherapy Drugs Market Scenario

The global market for immunotherapy drugs is experiencing significant growth and is projected to continue expanding in the coming years. Immunotherapy has emerged as a game-changing approach in cancer treatment, revolutionizing the way we combat the disease. It has shown remarkable efficacy and durable responses in various cancer types, leading to increased adoption and demand for immunotherapy drugs.

The market is driven by several factors, including the rising prevalence of cancer worldwide, the need for more effective and targeted treatment options, and the growing understanding of the immune system's role in cancer progression. Additionally, advancements in biotechnology and genomic research have facilitated the development of innovative immunotherapy drugs with improved safety profiles and enhanced therapeutic outcomes
Pharmaceutical companies and biotechnology firms are actively investing in research and development to discover and develop new immunotherapy drugs. They are focusing on expanding the indications for existing drugs and exploring novel immune targets and mechanisms. This continuous pipeline of drug development is expected to drive market growth.

Immunotherapy Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Abbott
  • PerkinElmer Inc
  • Illumina, Inc
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc
  • Sanofi
  • Johnson & Johnson Services, Inc
  • AbbVie Inc
  • Allergan
  • Merck & Co., Inc
  • Amgen Inc
  • Thermo Fisher Scientific
  • Teva Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals, Inc
  • Lilly
  • Bristol-Myers Squibb Company

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Immunotherapy Drugs Market Overview
3.1 Global Immunotherapy Drugs Market Historical Value (2016-2022)
3.2 Global Immunotherapy Drugs Market Forecast Value (2023-2031)
4 Global Immunotherapy Drugs Market Landscape
4.1 Global Immunotherapy Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Immunotherapy Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Applications
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End Users
5 Global Immunotherapy Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Immunotherapy Drugs Market Segmentation
6.1 Global Immunotherapy Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Monoclonal Antibodies
6.1.3 Adult Vaccines
6.1.4 Checkpoint Inhibitors
6.1.5 Interferons Alpha and Beta
6.1.6 Interleukins
6.1.7 Other Drugs
6.2 Global Immunotherapy Drugs Market by Applications
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Autoimmune and Inflammatory Diseases
6.2.4 Infectious Diseases
6.2.5 Others
6.3 Global Immunotherapy Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Immunotherapy Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Specialty Centres
6.4.4 Clinics
6.4.5 Others
6.5 Global Immunotherapy Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.5.5 Others
6.6 Global Immunotherapy Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Immunotherapy Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Immunotherapy Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Immunotherapy Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Immunotherapy Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Immunotherapy Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Abbott
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 PerkinElmer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Illumina, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 QIAGEN
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 AstraZeneca
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Sanofi
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Johnson & Johnson Services, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 AbbVie Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Allergan
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Merck & Co., Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Amgen Inc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Thermo Fisher Scientific
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Teva Pharmaceutical Industries Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Takeda Pharmaceutical Company Limited.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 GlaxoSmithKline plc.
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Lupin Pharmaceuticals, Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Lilly
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 Bristol-Myers Squibb Company
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
17.22 Boehringer Ingelheim International GmbH
17.22.1 Financial Analysis
17.22.2 Product Portfolio
17.22.3 Demographic Reach and Achievements
17.22.4 Mergers and Acquisitions
17.22.5 Certifications
18 Global Immunotherapy Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Abbott
  • PerkinElmer Inc.
  • Illumina Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Johnson & Johnson Services Inc.
  • AbbVie Inc.
  • Allergan
  • Merck & Co. Inc.
  • Amgen Inc.
  • Thermo Fisher Scientific
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited.
  • GlaxoSmithKline plc.
  • Lupin Pharmaceuticals Inc.
  • Lilly
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH

Methodology

Loading
LOADING...

Table Information